K 
Kubota Pharmaceutical Holdings Co 4596.T · JPY
Health Care · Tokyo Stock Exchange · 🇯🇵 Japan
55
+5.77%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in JPY, from our data supplier.
Revenue
¥21.3m
FY2016FY2025
Net income
−¥676.3m
FY2016FY2025
Free cash flow
−¥591.8m
FY2016FY2025
Shareholders' equity
¥1.81bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ¥21.3m | ¥27.2m | ¥39.9m | ¥8.3m | — | ¥37.8m | ¥37.8m | — | — | ¥846.3m |
| Gross profit | −¥3.1m | −¥43.6m | −¥59.0m | −¥56.5m | −¥59.2m | ¥37.8m | −¥45.9m | −¥21.2m | −¥29.1m | −¥4.0m |
| Research and development | ¥312.2m | ¥543.8m | ¥788.8m | ¥1.51bn | ¥2.04bn | ¥1.97bn | ¥2.76bn | ¥2.48bn | ¥2.38bn | ¥2.34bn |
| Operating income | −¥858.3m | −¥1.33bn | −¥1.39bn | −¥2.11bn | −¥2.64bn | −¥2.54bn | −¥3.29bn | −¥3.27bn | −¥3.62bn | −¥4.10bn |
| Net income | −¥676.3m | −¥1.33bn | −¥1.49bn | −¥2.02bn | −¥2.62bn | −¥2.44bn | −¥3.07bn | −¥3.05bn | −¥3.44bn | −¥3.91bn |
| Diluted earnings per share | -9.84 | -23.57 | -26.57 | -37.49 | -57.05 | -55.38 | -72.47 | -76.39 | -90.56 | -26.40 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | ¥1.98bn | ¥1.54bn | ¥3.02bn | ¥4.42bn | ¥4.83bn | ¥6.69bn | ¥8.74bn | ¥11.29bn | ¥13.40bn | ¥17.17bn |
| Cash and short-term investments | ¥1.92bn | ¥1.45bn | ¥2.77bn | ¥4.05bn | ¥3.98bn | ¥2.53bn | ¥7.97bn | ¥10.94bn | ¥1.17bn | ¥1.04bn |
| Total liabilities | ¥165.6m | ¥152.2m | ¥370.1m | ¥470.2m | ¥679.6m | ¥698.9m | ¥663.5m | ¥747.1m | ¥429.5m | ¥648.3m |
| Debt | ¥127.9m | ¥11.0m | ¥142.9m | ¥258.0m | ¥522.8m | ¥319.4m | ¥451.1m | ¥315.5m | ¥86.2m | ¥201.0m |
| Shareholders' equity | ¥1.81bn | ¥1.39bn | ¥2.65bn | ¥3.95bn | ¥4.15bn | ¥5.99bn | ¥8.08bn | ¥10.54bn | ¥12.97bn | ¥16.52bn |
| Shares outstanding | 69m | 57m | 56m | 54m | 46m | 44m | 42m | 40m | 38m | 148m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −¥581.1m | −¥1.20bn | −¥1.33bn | −¥2.07bn | −¥2.50bn | −¥2.17bn | −¥3.20bn | −¥2.56bn | −¥3.13bn | −¥3.01bn |
| Capital spending | −¥10.6m | −¥49.7m | −¥66.3m | −¥58.0m | −¥8.7m | −¥13.4m | −¥13.0m | −¥22.0m | −¥21.2m | −¥5.0m |
| Free cash flow | −¥591.8m | −¥1.25bn | −¥1.40bn | −¥2.13bn | −¥2.50bn | −¥2.18bn | −¥3.21bn | −¥2.58bn | −¥3.15bn | −¥3.02bn |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ¥3.0m | ¥4.7m | ¥3.1m | ¥5.5m | ¥5.5m | ¥7.2m | ¥10.0m | ¥7.4m |
| Gross profit | −¥17.5m | ¥3.2m | −¥15.5m | ¥4.2m | ¥1.7m | ¥6.4m | −¥8.5m | −¥11.0m |
| Operating income | −¥335.9m | −¥302.2m | −¥240.3m | −¥199.9m | −¥185.7m | −¥232.4m | −¥277.1m | −¥280.0m |
| Net income | −¥337.3m | −¥312.1m | −¥241.1m | ¥14.6m | −¥191.2m | −¥258.6m | −¥333.2m | −¥330.8m |
| Diluted earnings per share | -2.28 | -2.11 | -3.51 | 0.21 | -2.78 | -3.76 | -5.89 | -5.85 |
| Cash from operations | −¥288.0m | −¥280.0m | −¥145.0m | ¥5.0m | −¥180.0m | −¥261.0m | −¥248.0m | −¥255.0m |
| Capital spending | −¥1.0m | −¥10.0m | −¥2.0m | −¥4.0m | −¥4.0m | — | −¥14.0m | −¥4.0m |
| Free cash flow | −¥289.0m | −¥290.0m | −¥147.0m | ¥1.0m | −¥184.0m | — | −¥262.0m | −¥259.0m |
| Total assets | ¥1.78bn | ¥1.86bn | ¥1.98bn | ¥1.84bn | ¥1.21bn | ¥1.35bn | ¥1.54bn | ¥1.92bn |
| Cash and short-term investments | ¥1.58bn | ¥1.79bn | ¥1.92bn | ¥1.77bn | ¥1.14bn | ¥1.26bn | ¥1.45bn | ¥1.74bn |
| Debt | ¥15.3m | ¥18.5m | ¥14.0m | ¥13.2m | ¥12.8m | ¥16.4m | ¥10.2m | ¥60.5m |
| Shareholders' equity | ¥1.60bn | ¥1.68bn | ¥1.81bn | ¥1.73bn | ¥1.09bn | ¥1.21bn | ¥1.39bn | ¥1.70bn |
Financial ratios
Data as of 3 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2016 | FY2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | -14.7% | -160.4% | -148.0% | -685.0% | — | 100.0% | -121.6% | — | — |
| Operating margin | -4023.1% | -4896.0% | -3493.6% | -25584.3% | — | -6725.6% | -8702.7% | — | — |
| Net margin | -3169.7% | -4902.2% | -3734.6% | -24423.4% | — | -6450.6% | -8113.0% | — | — |
| Return on equity | -37.3% | -95.9% | -56.3% | -51.0% | -63.0% | -40.7% | — | — | — |
| Return on assets | -34.2% | -86.4% | -49.4% | -45.6% | -54.1% | -36.4% | — | — | — |
| Free cash flow yield | -12.4% | -30.3% | -33.8% | -55.8% | -80.9% | -73.1% | — | — | — |
| Revenue growth | -21.5% | -31.8% | 383.2% | — | — | 0.0% | — | -71.0% | -22.2% |
| Earnings growth | -49.3% | -10.5% | -26.1% | -23.0% | 7.3% | -20.5% | — | — | — |
| Current ratio | 12.51x | 10.12x | 10.14x | 11.59x | 8.53x | 12.67x | — | — | — |
| Debt to equity | 0.07x | 0.01x | 0.02x | 0.01x | 0.09x | 0.02x | — | — | — |
| Equity ratio | 91.6% | 90.1% | 87.7% | 89.4% | 85.9% | 89.6% | — | — | — |
| Interest coverage | -984.33x | -179.84x | -148.66x | -182.63x | -145.56x | -154.94x | — | — | — |
| R&D as a share of sales | 1463.4% | 2000.2% | 1977.6% | 18328.9% | — | 5221.1% | 7294.6% | — | — |
| Buybacks as a share of market value | -21.5% | -0.9% | -4.2% | -17.3% | -4.2% | -4.0% | — | — | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 37.2% | -10.8% | -38.8% |
| Operating income | -25.9% | -19.5% | -12.4% |
| Net income | -30.5% | -22.6% | -14.1% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | -96.3% | -167.9% | — | — |
| Operating margin | -4512.2% | -5891.2% | — | — |
| Net margin | -4140.4% | -5704.9% | — | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | -4.3 | -2.3 | -3.0 | -3.1 | -2.6 | -4.5 | -4.1 | -3.2 | -6.3 | -39.5 |
| Price to sales | 135.2 | 110.2 | 112.4 | — | — | 290.0 | 330.3 | — | — | 182.8 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.